United Therapeutics (UTHR) Set to Announce Quarterly Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR) is scheduled to be announcing its earnings results before the market opens on Wednesday, July 31st. Analysts expect the company to announce earnings of $6.24 per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating the consensus estimate of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. During the same quarter last year, the firm posted $4.86 earnings per share. United Therapeutics’s revenue for the quarter was up 33.7% compared to the same quarter last year. On average, analysts expect United Therapeutics to post $25 EPS for the current fiscal year and $27 EPS for the next fiscal year.

United Therapeutics Trading Up 1.3 %

NASDAQ UTHR traded up $4.27 during mid-day trading on Tuesday, hitting $339.54. The company’s stock had a trading volume of 160,050 shares, compared to its average volume of 488,941. United Therapeutics has a 52-week low of $208.62 and a 52-week high of $343.98. The stock’s fifty day simple moving average is $304.23 and its two-hundred day simple moving average is $258.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The firm has a market capitalization of $15.06 billion, a P/E ratio of 15.85, a price-to-earnings-growth ratio of 1.47 and a beta of 0.55.

Analyst Ratings Changes

UTHR has been the topic of several research reports. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Monday, July 15th. TD Cowen raised their price target on shares of United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Morgan Stanley lowered shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $310.00 to $321.00 in a report on Thursday, July 11th. Wells Fargo & Company increased their price objective on shares of United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, June 12th. Finally, Oppenheimer increased their price objective on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Two investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $330.64.

Insider Transactions at United Therapeutics

In other news, Director Nilda Mesa sold 266 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $318.58, for a total transaction of $84,742.28. Following the completion of the sale, the director now owns 5,107 shares of the company’s stock, valued at $1,626,988.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other United Therapeutics news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $258.09, for a total value of $929,124.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $33,551.70. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Nilda Mesa sold 266 shares of United Therapeutics stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total transaction of $84,742.28. Following the completion of the transaction, the director now directly owns 5,107 shares of the company’s stock, valued at approximately $1,626,988.06. The disclosure for this sale can be found here. Over the last quarter, insiders sold 100,884 shares of company stock valued at $29,994,539. 12.50% of the stock is currently owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.